Genetically modified non-human animals with humanized immunoglobulin locus
Genetically modified animals with humanized λ light chain immunoglobulin loci address the limitations of existing antibody production methods by enabling efficient production of humanized antibodies with enhanced affinity and diversity, suitable for drug discovery and research.
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO LTD
- Filing Date
- 2026-05-07
- Publication Date
- 2026-07-17
AI Technical Summary
Existing methods for generating human antibodies face challenges such as suboptimal binding affinity, immunogenicity, and limited diversity, particularly in transgenic animals with incomplete human antibody libraries, and there is a need for efficient production of humanized immunoglobulin loci, especially the λ light chain locus, to overcome these issues.
Genetically modified non-human animals are developed with human IGLV, IGLJ, and IGLC genes inserted at the endogenous λ light chain immunoglobulin locus or a safe harbor locus, such as Hipp11 or Rosa26, with operatively linked genes capable of rearrangement, and disruption of endogenous loci to enhance human antibody production.
These animals can efficiently produce humanized antibodies with improved binding affinity and diversity, reducing immunogenicity and manufacturing difficulties, and are suitable for drug discovery and research applications.
Smart Images
Figure 00000000_0000_ABST